BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37516668)

  • 1. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey.
    Taguchi A; Hagino H; Inoue D; Endo N; Society JO
    J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw.
    Taguchi A; Shiraki M; Sugimoto T; Ohta H; Soen S;
    Curr Med Res Opin; 2016 Jul; 32(7):1261-8. PubMed ID: 27007294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group.
    Taguchi A; Shiraki M; Tsukiyama M; Miyazaki T; Soen S; Ohta H; Nakamura T; Orimo H
    Calcif Tissue Int; 2015 Dec; 97(6):542-50. PubMed ID: 26210799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the Knowledge and Experience of Physicians and Dentists About Medication-Related Osteonecrosis of the Jaw in Osteoporotic Patients.
    Yamori M; Tamura M; Mikami M; Mori T; Noi M; Machida Y; Koshinuma S; Yamamoto G
    Int Dent J; 2021 Aug; 71(4):336-342. PubMed ID: 33518370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians' awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis.
    Supanumpar N; Pisarnturakit PP; Charatcharoenwitthaya N; Subbalekha K
    PLoS One; 2024; 19(1):e0297500. PubMed ID: 38277387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
    Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.
    Ishimaru M; Ono S; Morita K; Matsui H; Hagiwara Y; Yasunaga H
    J Oral Maxillofac Surg; 2022 Apr; 80(4):714-727. PubMed ID: 35033505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso).
    Madeira M; Rocha AC; Moreira CA; Aguiar ÁMM; Maeda SS; Cardoso AS; de Moura Castro CH; D'Alva CB; Silva BCC; Ferraz-de-Souza B; Lazaretti-Castro M; Bandeira F; Torres SR
    Arch Endocrinol Metab; 2021 May; 64(6):664-672. PubMed ID: 34033275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dentist's Perspective on the Need for Interdisciplinary Collaboration to Reduce Medication-Related Osteonecrosis of the Jaw.
    Griffin A; Brain P; Hancock C; Jeyapalina S
    Sr Care Pharm; 2022 Sep; 37(9):458-467. PubMed ID: 36038998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative focus group interview study of communication between patients, dentists and physicians for efficient osteonecrosis of the jaw practices.
    Choi Y; Park H; Hong N; Rhee Y; Park W
    BMJ Open; 2022 Mar; 12(3):e051054. PubMed ID: 35318228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals.
    Miranda-Silva W; Montezuma MA; Benites BM; Bruno JS; Fonseca FP; Fregnani ER
    Support Care Cancer; 2020 Nov; 28(11):5397-5404. PubMed ID: 32144584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
    Tröltzsch M; Tröltzsch M; Pautke C; Otto S
    HNO; 2022 Jul; 70(7):499-507. PubMed ID: 35050392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.